A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs

BACKGROUND: Administrative-claims data enable comparative effectiveness assessment using large numbers of patients treated in real-world settings. OBJECTIVE: To evaluate real-world relapses, healthcare costs and resource use in patients with MS newly initiating subcutaneous interferon beta-1a (sc IF...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowen, James D, Kozma, Chris M, Grosso, Megan M, Phillips, Amy L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299291/
https://www.ncbi.nlm.nih.gov/pubmed/30574342
http://dx.doi.org/10.1177/2055217318819031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299291/
https://www.ncbi.nlm.nih.gov/pubmed/30574342
http://dx.doi.org/10.1177/2055217318819031

Ejemplares similares